Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

cordlife
one chance, one choice.

PRESS RELEASE

Cordlife Appoints Tan Poh Lan as Group Chief Operating Officer; Strengthens Management Team

Singapore, 12th April 2016 – Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), a mother and child consumer healthcare company, is pleased to announce the appointment of Tan Poh Lan ("Ms. Tan") as Group Chief Operating Officer ("COO") of Cordlife with immediate effect.

As COO of Cordlife, Ms. Tan will be responsible for increasing the service offerings of Cordlife and growing the current core business. She will also work closely with the Board of Directors and Senior Management to strategise, streamline and improve operating performance.

Ms. Tan has 30 years of extensive experience in the private and public healthcare sectors. She was most recently Chief Executive Officer ("CEO") of Fortis Healthcare Singapore where she successfully aligned and integrated the businesses of Fortis Colorectal Hospital & Radlink, an outpatient imaging centre with a cyclotron and 3 general practitioner clinics, and established a Public-Private Partnership model with some government hospitals.

Notably, Ms. Tan was CEO of Gleneagles Hospital in Singapore from April 2008 to September 2011. Under her leadership, she expanded the hospital's service offerings, built up one of the top services lines in the Hospital, and established a centre of excellence for liver diseases and transplant.

Ms. Tan was also, formerly, the CEO for Vinmec International Hospital in Hanoi, Vietnam and Parkway East Hospital (formerly East Shore Hospital). She developed a five year strategic plan and a quality framework for Vinmec International Hospital, and was instrumental in initiating the master plan for Parkway East Hospital for upgrading of its building and services.

Dr. Ho Choon Hou, Chairman and Non Executive Director of Cordlife, said, "On behalf of the Board, we welcome Ms. Tan Poh Lan as our new Group COO. We believe the appointment of Ms. Tan, being a veteran in the Healthcare Industry, with her skills in operations, personnel management, performance improvement and business development will be integral as we pursue our next stage of growth to be a leading mother and child consumer healthcare company. We look forward to her valuable contributions in the coming years."

Ms. Tan holds a Master of Business Administration from National University of Singapore and graduated with Honours in Occupational Therapy from University of Queensland, Australia.

– The End –

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia, Malaysia and the Philippines[1]. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks. The Group also extends its products and services to families in the region through its associate in Thailand and sub-licensing partner in China.

Cordlife has also established a new Diagnostics Business Unit. This initiative is part of Cordlife's vertical growth plan to offer complementary products and services that cater to the mother and child segment. Metascreen™, a comprehensive metabolic screening test currently designed for newborn babies, is the first of Cordlife's new product and service offerings in diagnostics. A newly screening test, Non-Invasive Prenatal Testing which was launched in 2015 can analyse fatal DNA in mother's blood to screen for fetal chromosomal abnormalities. Besides, Cordlife also launched another screening test, Eyescreen™ which would enable the early detection of vision problems in children.

Aside from organic growth strategies to enhance brand awareness in key markets, Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. In December 2015, Cordlife increased its stake in StemLife Berhad ("StemLife Malaysia"), a Ministry of Health licensed cord blood banking facility listed on the ACE Market of Bursa Malaysia, thereby making StemLife Malaysia a subsidiary of Cordlife Group Limited. Cordlife currently has an aggregate of 222,472,929 shares, representing an approximate 89.88% direct stake.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks) and also has been accredited by the Foundation for the Accreditation of Cellular Therapy ("FACT") in 2015, becoming the first dual-accredited cord blood bank in South East Asia. With this, the Group joins five other private cord blood banks globally to achieve dual-accreditation. The Group is one of the first private cord blood banks in Asia to release cord blood units for transplants, and for treatment of cerebral palsy as well as for other therapeutic uses. As at February 2016, Cordlife Group and subsidiaries have released over 500 stem cell units that were used successfully to support transplants and therapies.

In April 2013, Cordlife was the first private cord blood bank in Asia to launch a GMP compliant automated stem cell processing system that can produce consistently high cell recoveries from cord blood. Cordlife also has a strategic alliance in China with CordLabs Asia Pte. Ltd. (CordLabs Asia"), a wholly-owned subsidiary of CellResearch

[1] Source: Deloitte & Touche Financial Advisory Services Limited report, October 2014

Corporation Pte. Ltd. ("CRC"), which gives the Group the exclusive rights to market their technology in relation to the provision of human postnatal cord lining storage services and training and the transfer of the know-how, in India, Indonesia, Malaysia, Philippines, Singapore, Hong Kong and Thailand. In February 2016, Cordlife acquired CRC convertible note and shares for approximately S$8.4 million.

Cordlife's track record has won the Group many accolades and awards, including: One of the "Best Under a Billion" companies by Forbes Asia (November 2015); Runner-up of the 16th SIAS Investors' Choice Award, Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category (October 2015); "My Favourite Cord Blood Bank" by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader's Choice by Child Magazine; "Most Transparent Company 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards.

For more information on CGL, visit http://cordlife.listedcompany.com/

ISSUED ON BEHALF OF	:	Cordlife Group Limited
BY	:	Financial PR Pte Ltd 4 Robinson Road #04-01 The House of Eden Singapore 048543
CONTACT	:	Mr Kamal Samuel / Mr Ngo Yit Sung
OFFICE	:	6438-2990
EMAIL	:	kamal@financialpr.com.sg / yitsung@financialpr.com.sg